EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modular in vitro evaluation of buparlisib-polymeric nanomedicines in 2D and 3D models of glioblastoma

Jarmila Havelkova, Yuriy Petrenko, Anna Stehlikova, Dana Marekova, Katerina Peskova, Michal Pechar, Martin Studenovsky, Tomáš Etrych, Robert Pola, Pavla Jendelova

Frontiers in Toxicology · 01.07.2026 · 8

DOI: 10.3389/ftox.2026.1783704 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Toxicology, online erschienen am 01.07.2026. Verfasst von Jarmila Havelkova und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroregeneration, Institute of Experimental Medicine, Czech Academy of Sciences, Prague, Czechia. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grantová Agentura České Republiky, Ministerstvo Školství, Mládeže a Tělovýchovy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In this study, we developed a modular in vitro platform that integrates advanced polymer–drug conjugation chemistry with stepwise cytotoxicity screening in both 2D (monolayer) and 3D (spheroids) glioblastoma (GBM) models. Buparlisib was selected as the model therapeutic agent due to its well-characterised mechanism of action, high blood–brain barrier permeability, and relevance to PI3K-targeted therapy.

Methods

Two mechanistically distinct conjugation strategies were explored using N-(2-hydroxypropyl)methacrylamide-based copolymers (pHPMA). The first strategy was based on a redox-sensitive disulphide linkage designed for intracellular glutathione-triggered release, whereas the second used an azide-bearing derivative compatible with strain-promoted azide–alkyne cycloaddition. Drug release was assessed by high-performance liquid chromatography. Biological activity was systematically evaluated in U87MG, U118MG, and T98G cells under 2D conditions using a resazurin-based metabolic activity assay. Subsequently, the more promising disulphide-based formulations were assessed in 3D spheroids by metabolic activity measurements and live-cell monitoring of spheroid growth dynamics.

Results

Free buparlisib showed the strongest inhibitory effect, while its modification and polymer conjugation reduced the apparent activity. Nevertheless, the disulphide-based derivative and polymer conjugate retained concentration-dependent activity, whereas the azide-based polymer conjugate showed minimal effects. Moreover, treatment responses differed between cell lines and between 2D and 3D models.

Discussion

Overall, linker chemistry, cell-line-specific behaviour, and model dimensionality strongly influenced the biological performance of the polymeric buparlisib formulations. The redox-sensitive polymer conjugate therefore represents the more promising strategy for further development.

Schlagwörter

Stichwörter der Autor:innen

2D and 3D modelsBuparlisib (BKM120)drug deliverydrug evaluationglioblastomananomedicinespolymer-drug conjugatesspheroids

Autor:innen und Institutionen

  • Department of Neuroregeneration, Institute of Experimental Medicine, Czech Academy of Sciences, Prague, Czechia.
  • Laboratory of Biomaterials and Tissue Engineering, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
  • Faculty of Science, Charles University, Prague, Czechia.
  • Department of Biomedical Polymers, Institute of Macromolecular Chemistry, Czech Academy of Sciences, Prague, Czechia.

Förderung

  • Grantová Agentura České Republiky
  • Ministerstvo Školství, Mládeže a Tělovýchovy

Zitieren

APA

Havelkova, J., Petrenko, Y., Stehlikova, A., Marekova, D., Peskova, K., Pechar, M., Studenovsky, M., Etrych, T., Pola, R., & Jendelova, P. (2026). Modular in vitro evaluation of buparlisib-polymeric nanomedicines in 2D and 3D models of glioblastoma. Frontiers in Toxicology, 8. https://doi.org/10.3389/ftox.2026.1783704

Vancouver

Havelkova J, Petrenko Y, Stehlikova A, Marekova D, Peskova K, Pechar M, et al. Modular in vitro evaluation of buparlisib-polymeric nanomedicines in 2D and 3D models of glioblastoma. Frontiers in Toxicology. 2026;8. doi:10.3389/ftox.2026.1783704

BibTeX
@article{Havelkova2026,
  author = {Havelkova, Jarmila and Petrenko, Yuriy and Stehlikova, Anna and Marekova, Dana and Peskova, Katerina and Pechar, Michal and Studenovsky, Martin and Etrych, Tomáš and Pola, Robert and Jendelova, Pavla},
  title = {Modular in vitro evaluation of buparlisib-polymeric nanomedicines in 2D and 3D models of glioblastoma},
  journal = {Frontiers in Toxicology},
  year = {2026},
  volume = {8},
  doi = {10.3389/ftox.2026.1783704}
}
Kostenlos starten →